Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Sarah Grillo / Axios

Pharmacists have been among the most vocal opponents of the drug pricing tactics that pharmacy benefit managers use. PBMs pay pharmacies for each filled prescription, but pharmacists, especially those running independent stores, say the big players are squeezing them by paying out wildly differing rates.

Key quote: "It is an absolute bloodbath for pharmacies right now," said Antonio Ciaccia, a top lobbyist with the Ohio Pharmacists Association. "When things are subjective and they're unclear, that is when the PBM sees opportunity."

The details: PBMs use "maximum allowable cost lists" (better known as "MAC lists") to determine what to charge employers for drugs and how to pay pharmacies. Those lists, which aren't publicly available, allow companies like CVS, Express Scripts and OptumRx to charge employers higher rates, pay pharmacies lower rates, and then pocket the difference.

  • Several independent pharmacists who were interviewed for this story said their contracts with PBMs are pretty much take-it-or-leave-it offers, and they often have little to no visibility into what MAC lists are being used.
  • "Realistically, we can't not sign the contract because we'd lose our patient base," said one independent pharmacist. "If you try to line out stuff you don't agree with, they say, 'We only accept clean contracts.'"
  • The pharmacist asked not to be named because the pharmacy's contract with CVS prohibits anyone from making "damaging, derogatory, or unfavorable public statements regarding a Caremark Party." CVS said that language was "standard."
  • The pharmacist shared a spreadsheet of 88 common generic drugs that the store fills, like lisinopril and omeprazole. For all but eight of those generics, the independent pharmacy was paid less than a chain pharmacy. For some drugs, the independent's reimbursement was more than 80% lower.
  • "We can't sustain taking these kinds of losses," said a different pharmacist in Florida.
  • Pharmacists in multiple states said CVS in particular had lowered their rates heavily in 2017. Some also said they got letters from CVS asking if they wanted to sell their store.

The other side: CVS spokeswoman Christine Cramer said in an email that "on an aggregate basis, we reimburse independent pharmacies at a higher rate than larger regional and national chains." She also said some pharmacist lobbying groups are painting a "skewed picture of the reimbursement they receive from CVS Caremark by cherry-picking some claims."

From the Express Scripts template:

"Average Wholesale Price" or "AWP" means the average wholesale price of a prescription drug as identified by drug pricing services such as Medi-Span or other source recognized in the retail prescription drug industry selected by ESI (the "Pricing Source").
"MAC List" means a list of off-patent prescription drugs or supplies subject to maximum reimbursement payment schedules developed or selected by ESI.

Other parts of the series:

Go deeper

Dems race to address, preempt stimulus fraud claims

Illustration: Aïda Amer/Axios

Biden officials are working to root out the systematic fraud in unemployment and Paycheck Protection Program claims that plagued the Trump administration’s efforts to boost the economy with coronavirus relief money, Gene Sperling told House committee chairmen privately this week.

Why it matters: President Biden just signed another $1.9 trillion of aid into law, with Sperling tapped to oversee its implementation. And the administration is asking Congress to approve another $2.2 trillion for the first phase of an infrastructure package.

3 hours ago - Politics & Policy

Scoop: Biden close to picking Nick Burns as China ambassador

Nicholas Burns. Photo: Alex Wong/Getty Images

Nicholas Burns, a career diplomat, is in the final stages of vetting to serve as President Biden’s ambassador to China, people familiar with the matter tell Axios.

Why it matters: Across the administration, there's a consensus the U.S. relationship with China will be the most critical — and consequential — of Biden's presidency. From trade to Taiwan, the stakes are high. Burns could be among the first batch of diplomatic nominees announced in the coming weeks.

Biden's Russian sanctions likely to achieve little

President Biden announces new sanctions against Russia. Photo: Chip Somodevilla/Getty Images

Despite bold talk from top administration officials, there's little reason to think the Russia sanctions package President Biden announced Thursday will do anything to alter Russian President Vladimir Putin's behavior or calculus.

Why it matters: While it's true some elements of the package — namely, the targeting of Russia's sovereign debt — represent significant punitive measures against Moscow, it leaves plenty of wiggle room for the Russian president.

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!